SG11201804484YA - Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy - Google Patents
Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathyInfo
- Publication number
- SG11201804484YA SG11201804484YA SG11201804484YA SG11201804484YA SG11201804484YA SG 11201804484Y A SG11201804484Y A SG 11201804484YA SG 11201804484Y A SG11201804484Y A SG 11201804484YA SG 11201804484Y A SG11201804484Y A SG 11201804484YA SG 11201804484Y A SG11201804484Y A SG 11201804484YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- chemotherapy
- dompe
- treatment
- induced
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16151618.2A EP3192504A1 (en) | 2016-01-15 | 2016-01-15 | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy |
| EP16190871 | 2016-09-27 | ||
| PCT/EP2017/050637 WO2017121838A1 (en) | 2016-01-15 | 2017-01-13 | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804484YA true SG11201804484YA (en) | 2018-07-30 |
Family
ID=57906595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804484YA SG11201804484YA (en) | 2016-01-15 | 2017-01-13 | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US12268671B2 (enExample) |
| EP (1) | EP3402474B1 (enExample) |
| JP (1) | JP7049254B2 (enExample) |
| KR (1) | KR102737378B1 (enExample) |
| CN (1) | CN108463219B (enExample) |
| AU (1) | AU2017207850B2 (enExample) |
| CA (1) | CA3009438A1 (enExample) |
| CY (1) | CY1125297T1 (enExample) |
| DK (1) | DK3402474T3 (enExample) |
| ES (1) | ES2893701T3 (enExample) |
| HR (1) | HRP20211527T1 (enExample) |
| HU (1) | HUE056606T2 (enExample) |
| IL (1) | IL260373B (enExample) |
| LT (1) | LT3402474T (enExample) |
| MA (1) | MA43861A (enExample) |
| MX (1) | MX388815B (enExample) |
| PL (1) | PL3402474T3 (enExample) |
| RS (1) | RS62427B1 (enExample) |
| SG (1) | SG11201804484YA (enExample) |
| SI (1) | SI3402474T1 (enExample) |
| SM (1) | SMT202100571T1 (enExample) |
| WO (1) | WO2017121838A1 (enExample) |
| ZA (1) | ZA201803486B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101914358B1 (ko) * | 2017-01-18 | 2018-11-02 | 현대로템 주식회사 | 실내등 제어회로 및 이를 포함하는 철도차량 |
| CN111343973A (zh) * | 2017-10-24 | 2020-06-26 | 多姆皮制药公司 | 用于治疗一些肉瘤的il-8抑制剂 |
| EP3476390A1 (en) | 2017-10-24 | 2019-05-01 | Dompé farmaceutici S.p.A. | Il-8 inhibitors for use in the treatment of sarcomas |
| EP3498269A1 (en) * | 2017-12-12 | 2019-06-19 | Dompé farmaceutici S.p.A. | C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain |
| CA3196979A1 (en) * | 2020-11-05 | 2022-05-12 | Icahn School Of Medicine At Mount Sinai | Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis |
| EP4052702A1 (en) * | 2021-03-04 | 2022-09-07 | Dompé farmaceutici S.p.a. | Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures |
| EP4397305A1 (en) * | 2023-01-05 | 2024-07-10 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1303249B1 (it) | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| HRP20090681T1 (hr) | 2004-03-23 | 2010-02-28 | Dompe' S.P.A. | Derivati 2-fenilpropionske kiseline i farmaceutski pripravci koji ih sadrže |
| EP2066335A4 (en) * | 2006-09-26 | 2010-01-20 | Univ Case Western Reserve | ZYTOKINSIGNALISIERUNG |
| EP2166006A1 (en) | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| CR20160557A (es) | 2014-05-29 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2 |
| KR20170036753A (ko) * | 2014-07-31 | 2017-04-03 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 화학요법 유도된 말초 신경병증 (cipn)의 예방 및/또는 치료를 위한 cxcr2 길항제의 용도 |
-
2017
- 2017-01-13 EP EP17701646.6A patent/EP3402474B1/en active Active
- 2017-01-13 JP JP2018537469A patent/JP7049254B2/ja active Active
- 2017-01-13 ES ES17701646T patent/ES2893701T3/es active Active
- 2017-01-13 MX MX2018008614A patent/MX388815B/es unknown
- 2017-01-13 MA MA043861A patent/MA43861A/fr unknown
- 2017-01-13 SI SI201730924T patent/SI3402474T1/sl unknown
- 2017-01-13 KR KR1020187019923A patent/KR102737378B1/ko active Active
- 2017-01-13 WO PCT/EP2017/050637 patent/WO2017121838A1/en not_active Ceased
- 2017-01-13 CA CA3009438A patent/CA3009438A1/en active Pending
- 2017-01-13 HU HUE17701646A patent/HUE056606T2/hu unknown
- 2017-01-13 PL PL17701646T patent/PL3402474T3/pl unknown
- 2017-01-13 US US16/066,072 patent/US12268671B2/en active Active
- 2017-01-13 LT LTEPPCT/EP2017/050637T patent/LT3402474T/lt unknown
- 2017-01-13 DK DK17701646.6T patent/DK3402474T3/da active
- 2017-01-13 CN CN201780005946.9A patent/CN108463219B/zh active Active
- 2017-01-13 AU AU2017207850A patent/AU2017207850B2/en active Active
- 2017-01-13 SG SG11201804484YA patent/SG11201804484YA/en unknown
- 2017-01-13 SM SM20210571T patent/SMT202100571T1/it unknown
- 2017-01-13 RS RS20211209A patent/RS62427B1/sr unknown
- 2017-01-13 HR HRP20211527TT patent/HRP20211527T1/hr unknown
-
2018
- 2018-05-25 ZA ZA2018/03486A patent/ZA201803486B/en unknown
- 2018-07-02 IL IL260373A patent/IL260373B/en active IP Right Grant
-
2021
- 2021-10-14 CY CY20211100886T patent/CY1125297T1/el unknown
-
2025
- 2025-02-27 US US19/064,835 patent/US20250195479A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12268671B2 (en) | 2025-04-08 |
| MX2018008614A (es) | 2018-11-19 |
| CN108463219A (zh) | 2018-08-28 |
| CA3009438A1 (en) | 2017-07-20 |
| US20250195479A1 (en) | 2025-06-19 |
| EP3402474A1 (en) | 2018-11-21 |
| SI3402474T1 (sl) | 2021-12-31 |
| AU2017207850A1 (en) | 2018-06-21 |
| SMT202100571T1 (it) | 2021-11-12 |
| BR112018013570A2 (pt) | 2018-12-11 |
| ES2893701T3 (es) | 2022-02-09 |
| DK3402474T3 (da) | 2021-10-11 |
| LT3402474T (lt) | 2021-11-25 |
| MA43861A (fr) | 2021-05-05 |
| MX388815B (es) | 2025-03-20 |
| PL3402474T3 (pl) | 2021-12-27 |
| KR20180101390A (ko) | 2018-09-12 |
| HRP20211527T1 (hr) | 2021-12-24 |
| RS62427B1 (sr) | 2021-11-30 |
| CY1125297T1 (el) | 2023-03-24 |
| AU2017207850B2 (en) | 2022-06-30 |
| ZA201803486B (en) | 2019-09-25 |
| NZ743344A (en) | 2024-05-31 |
| WO2017121838A1 (en) | 2017-07-20 |
| US20190015391A1 (en) | 2019-01-17 |
| JP2019501948A (ja) | 2019-01-24 |
| CN108463219B (zh) | 2021-09-17 |
| EP3402474B1 (en) | 2021-07-21 |
| JP7049254B2 (ja) | 2022-04-06 |
| HUE056606T2 (hu) | 2022-02-28 |
| IL260373B (en) | 2021-03-25 |
| KR102737378B1 (ko) | 2024-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
| SG11201909019SA (en) | Methods of treatment using a jak inhibitor compound | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201809024UA (en) | Cancer immunotherapy by immune activation or immune modulation via globo series antigens | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201907505TA (en) | Low-viscosity, high-concentration evolocumab formulations and methods of making the same | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia |